+

WO2008065673A1 - Procédé de fabrication de polypeptides exempts de méthionine n-terminale dans des cellules hôtes microbiennes - Google Patents

Procédé de fabrication de polypeptides exempts de méthionine n-terminale dans des cellules hôtes microbiennes Download PDF

Info

Publication number
WO2008065673A1
WO2008065673A1 PCT/IN2007/000012 IN2007000012W WO2008065673A1 WO 2008065673 A1 WO2008065673 A1 WO 2008065673A1 IN 2007000012 W IN2007000012 W IN 2007000012W WO 2008065673 A1 WO2008065673 A1 WO 2008065673A1
Authority
WO
WIPO (PCT)
Prior art keywords
skc
streptokinase
coli
agents
terminal methionine
Prior art date
Application number
PCT/IN2007/000012
Other languages
English (en)
Inventor
Kedarnath Sastry
Akundi Venkata Sriram
Anuj Goel
Sandeep Vishwanath Kamath
Hardik Valera
Mayank Kumar Garg
Suma Sreenivas
Malur Dattatreya Swetha
Amrita Basu
Reena Nichinmetla Raghunandan
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Priority to MX2009005764A priority Critical patent/MX2009005764A/es
Priority to EP07706183A priority patent/EP2097520A4/fr
Publication of WO2008065673A1 publication Critical patent/WO2008065673A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention provides a method of obtaining a N-terminal methionine free polypeptides in E.coli by constructing a plasmid to express a Ubiquitin like protein SMT3 -polypeptide fusion protein in the E.coli cytoplasm, which is cleaved by the co- expressed ULPl protease.
  • the SMT3 -polypeptide fusion protein of the instant invention is specifically a SMT3 -Streptokinase, a SMT3 -Streptokinase fusion protein.
  • Streptokinase is a thrombolytic drug approved for use in acute myocardial infarction and thromboembolism.
  • Streptokinase acts on plasminogen to convert it into plasmin which in turn degrades fibrin into soluble products.
  • Streptokinase C (SKC) is synthesized as a precursor protein of 440 amino acids from which a 26 amino acid signal sequence is cleaved off before secretion from hemolytic Streptococci.
  • Both native (non-recombinant) and recombinant SKC (rSKC) are commercially available. In two recent studies it was reported that, of the sixteen SKC preparations available in the market, only three showed potency fulfilling the criteria established by European Pharmacopoeia (Longstaff C, Thelwell C, and Whitton C, J. Thromb.
  • SKC potency evaluation is done by two in-vitro assays - one in the absence of fibrin using a chromogenic substrate and another using fibrin as a substrate for clot- lysis where the activity is declared in international reference units. The value obtained by these two assays is identical when native streptokinase is tested. If the manufacturer of the recombinant SKC choose only one method (either chromogenic or clot-lysis assay) to determine potency, it is possible that the potency values obtained could be either be overestimated or underestimated. This under or over estimation has dramatic consequences during treatment. If the dose administered is lower than recommended, then reperfusion rate could be lower.
  • Met 0 SKC methionine free at its N-terminus
  • the method used to manufacture Met 0 SKC should be also simple, efficient and commercially viable.
  • recombinant proteins are expressed in E.coli, it is necessary to have ATG codon, encoding Methionine for initiation of protein synthesis.
  • heterologus proteins are expressed in E.coli, the N-terminal methionine may be removed in vivo, by methionine amino peptidase encoded by the genome of E.coli.
  • the N-terminal methionine fails to be removed.
  • One method to solve this problem is to employ a tag at the N-terminus of the recombinant protein with suitable cleavage site to construct a fusion protein.
  • Methods for producing a recombinant protein with an N- or C-terminal tag are well known in the art.
  • the tag is removed from the purified recombinant protein by enzymatic cleavage in vitro, to generate the authentic N-terminus bearing protein.
  • Many tags are available to the practitioners of art.
  • Glutathione S-transferase GST
  • GST Glutathione S-transferase
  • This method is cumbersome as Factor Xa protease has to be produced separately and purified before its use in vitro for fusion protein cleavage.
  • many of the proteases also cleave the fusion protein at various non-canonical sites reducing overall yield of recombinant protein.
  • the table below summarizes the current state of art, wherein only enterokinase, Factor Xa protease and intein tags allow cleavage in a specific manner, without leaving behind extra amino acids at the N-terminus.
  • tags made available for various N- terminus cleavages are due to the fact that it is not possible to predict whether a particular tag will provide the desired result.
  • Two common reasons for using a tag are to improve the expression of a recombinant protein or make the expressed recombinant protein soluble. Often, recombinant heterologus proteins expressed in E.coli cytoplasm become insoluble forming the so called "inclusion bodies" and the use of tag may make the protein soluble at least partially. In other cases the tag may make the purification process simpler. For example adding a His tag to the expressed recombinant protein, allows simple and rapid purification using metal affinity chromatography step.
  • His tag (comprising of six or ten Histidine residues) could be fused to another tag (for example, SMT3) which could make the recombinant protein more soluble.
  • SMT3 another tag
  • His tag is easy purification from cytoplasm, using metal affinity chromatography.
  • a second reason for adding tags to N-terminus is to make the proteins stable and prevent its degradation by proteases in E.coli cytoplasm. Small peptides/proteins with low molecular weight ( ⁇ 10 kD) are often degraded rapidly when expressed by themselves in E.coli. For example, small peptides like GLP-I, insulin, etc have been shown to be stable only when they are expressed along with a tag at N-terminus.
  • Small Ubiquitin related Modifier protein is a protein which is covalently attached post translationally to N-terminus of various proteins.
  • SMT3 from Saccharomyces cerevisiae is an example of Small Ubiquitin like protein.
  • Ubiquitin and Ubiquitin like proteins play an important role in various cell functions (nuclear metabolism, cell proliferation, autophagy, etc.) by modulating protein structure and function.
  • ULPl protease releases SMT3 tag from proteins to which it is attached.
  • prokaryote like E.coli has neither SMT3 nor ULPl protease gene in its genome. Hence use of SMT3 tag in prokaryotes is much more convenient.
  • Ubiquitin-like-specific protease 1 is deubiquitinating enzyme which cleaves the C-termini of SMT3 and deconjugate SMT3 from the side chains of lysines (Li, SJ. and Hochstrasser, M. (1999) Nature 398, 246-251).
  • Three-dimensional structure of a complex between SMT3 and ULPl show that certain surface features of SMT3 are recognized by ULPl that make the interaction specific (Mossessova, E. and Lima, CD. (2000) MoI. Cell. 5, 865-876).
  • the catalytic domain (amino acids 403-621) of ULPl is sufficient for deconjugation of SMT3 from fusion proteins and has been show to be functional when expressed in E.coli (Mossessova, E. and Lima, CD. (2000) MoI. Cell. 5, 865-876).
  • the principal object of the present invention is to produce N-terminal methionine free polypeptides in microbial host cells. Another object of the present invention is to produce N-terminal methionine free polypeptides in bacterial and fungal host cells.
  • Yet another object of the present invention is to produce N-terminal methionine free streptokinase in E.coli host cells.
  • Still another object of the present invention is to develop a method for the making of N-terminal methionine free polypeptides in microbial host cells.
  • Still another object of the present invention is to develop a method for the making of
  • Still another object of the present invention is to prepare a pharmaceutical composition comprising Met 0 hGH along with one or more pharmaceutically acceptable excipients.
  • a method of making N-terminal methionine free polypeptide in a recombinant microbial host cell comprising: (i) preparing an expression construct containing a DNA encoding a polypeptide of interest; (ii) preparing an expression construct containing a DNA encoding a protease enzyme (iii) cloning both the expression constructs of (i) and
  • N-terminal methionine free streptokinase a method of making N-terminal methionine free streptokinase in E.coli host comprising: (i) preparing an expression construct containing a DNA encoding a SUMO- streptokinase flision protein; (ii) preparing an expression construct containing a DNA encoding a UIp 1 protease; (iii) cloning both the expression construct of (i) and (ii) into an E.coli host; (iv) fermentation of the transformants and inducing co- expression; and (v) obtaining the N-terminal methionine free streptokinase by lysing the cells and purifying the protein; a substantially pure recombinant N-terminal methionine free streptokinase (Met 0
  • E.coli BL21 (DE3) transformed with pET SKC plasmid.
  • Fig.3. Map of the plasmid with mutated version of E.coli MAP coding sequence driven by native promoter. Fig.4. SDS-PAGE analysis of total cell lysate from induced and uninduced cultures of
  • E.coli BL21 (DE3) transformed with pET ULPl plasmid.
  • Fig.5. Schematic diagram showing method of construction of plasmid for co-expression of Saccharomyces cerevisiae ULPl in E.coli
  • FIG.6 Schematic representation of SMT3 and SKC gene fusion
  • Fig.7 is a map of the plasmid with SMT3-SKC fusion coding sequence driven by a T7 promoter sequence
  • Fig.8 SDS-PAGE analysis of total cell lysates from induced and uninduced cultures of
  • E.coli Bill (DE3) co-transformed with pET SKC and pTrcULPl/pACYC plasmids.
  • Fig:9 Illustration explaining the soluble chromogen assay and clot lysis assay.
  • the present invention is in relation to a method of making N-terminal methionine free polypeptide in a recombinant microbial host cell comprising: (i) preparing an expression construct containing a DNA encoding a polypeptide of interest; (ii) preparing an expression construct containing a DNA encoding a protease enzyme (iii)cloning both the expression constructs of (i) and (ii) into the host cell to obtain transformant;
  • microbial host cell is selected from a group comprising bacteria and fungi.
  • N-terminal methionine free polypeptide is btained either by secrection or by lysing the cells and purifying the protein.
  • polypeptide of interest is a hormone, an enzyme or a therapeutic protein.
  • hormone is a growth hormone, luteinising hormone, or a natriuretic peptide
  • Still another embodiment of the present invention wherein the therapeutic enzyme is streptokinase
  • Still another embodiment of the present invention wherein the growth hormone is hGH
  • the present invention is in relation to a method of making N-terminal methionine free streptokinase in E.coli host comprising:
  • the expression construct is a pET vector containing a DNA encoding SMT3-Streptokinase fusion protein. Still yet another embodiment of the present information, wherein the expression construct ⁇ is a pACYC184 vector containing a DNA encoding UIp 1 protease operationally linked to a promoter.
  • Still yet another embodiment of the present information wherein the DNA encoding UIp 1 protease operationally linked to a promoter is integrated into E.coli genome.
  • N-terminal methionine free streptokinase is Met 0 SKC of Seq. ID no. 17, with potency identical to native SKC.
  • the present invention is in relation to a substantially pure recombinant N-terminal methionine free streptokinase (Met 0 SKC)
  • the present invention is in relation to a pharmaceutical composition comprising streptokinase (Met 0 SKC) which is substantially free of Met-SKC along with one or more pharmaceutically acceptable excipient
  • the present invention is in relation to a pharmaceutical composition
  • a pharmaceutical composition comprising Met 0 hGH which is substantially free of N-terminal methionine-hGH along with one or more pharmaceutically acceptable excipients.
  • the pharmaceutical excipients are selected from a group comprising granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents and spheronization agents.
  • Recombinant SKC when expressed in E.coli without a tag at the N-terminus results in a mixture of molecules with and without Methionine.
  • the physicochemical properties of the rSKC molecules with and without Methionine are very similar and are hence difficult to separate by simple techniques.
  • a vector has been developed in which PCR amplified SMT3 coding sequence has been fused in frame with PCR amplified coding sequence of mature SKC (Met 0 SKC) and cloned into a vector in which the fusion protein sequence is operationally linked to phage T7 promoter.
  • This recombinant vector is cloned to express the recombinant SMT3-Met° SKC fusion protein in a genetically engineered E.coli host like BL21 (DE3) or BL26 (DE3) strains, upon induction with isopropyl-beta-D-thiogalactopyranoside (IPTG).
  • the recombinant SMT3 -SKC fusion protein is expressed into the E.coli cytoplasm and is cleaved by the by co-expressed ULPl in vivo.
  • the ULPl protease very specifically recognizes the three dimensional features of SMT3 protein, in addition to Gly-Gly sequence, in the C- terminus and cleaves the SMT3 to release Met 0 SKC. This simplifies the method of cleavage as opposed to in vitro cleavage which requires a second fermentation to produce ULPl protease.
  • the ULPl protease is expressed in the same cell by a compatible, low copy number recombinant plasmid vector into which PCR amplified coding sequence of ULPl protease is cloned operationally linked to tac promoter which is also inducible by IPTG.
  • the instant invention allows a simple method of producing Met 0 SKC in large quantities using recombinant techniques for use in pharmaceutical compositions.
  • the alternate methods described in literature involve over expression of E.coli gene coding for methionine amino peptidase (MAP). MAP over expression does not always help in removal of methionine from the N-terminus for various reasons like the nature of penultimate amino acid, secondary structure of the protein near the N-terminus, etc.
  • SMT3 coding sequence was PCR amplified from genomic DNA of Saccharomyces cerevisiae.
  • SKC mature form coding nucleic acid fragment was amplified from the genomic DNA of Streptococcus equisimilis.
  • the C- terminal end of SMT3 (ending in amino acids Gly-Gly) was fused in frame to N- terminal of Met 0 SKC (beginning with amino acids Ile-Ala).
  • This fused PCR product was cloned into pET vector using which recombinant proteins could be made by induction with IPTG after transformation into appropriate commercially available genetically engineered E.coli host like BL21 (DE3), into whose genome lacUV5 promoter driven T7 phage polymerase coding sequence has been integrated (Novagen, Madison, USA).
  • PCR technique was used to amplify ULPl protease gene from Saccharomyces cerevisiae genome and cloned into a low copy number vector (p AC YC) vector. The expression of ULPl was driven by tac promoter, which is also induced by IPTG.
  • ULPl protease by integration of the ULPl gene into E.coli genome is also possible.
  • the ULPl gene could be targeted to msbB gene coding sequence, the disruption of which could cause a reduction in the levels of endotoxin from the E.coli host, helping in improving the quality of therapeutic protein by reduction of endotoxin impurity.
  • msbB gene coding sequence the disruption of which could cause a reduction in the levels of endotoxin from the E.coli host, helping in improving the quality of therapeutic protein by reduction of endotoxin impurity.
  • SKC gene The source of DNA for mature Streptokinase encoding gene was the genomic DNA isolated from Streptococcus sp. strain BICC #7869 (MTCC 389). Genomic DNA was isolated using a commercially available (Qiagen) kit following manufacturer's instructions. The following primers were used for the amplification of the SKC gene.
  • SKCFPl 5' CATATGATTGCTGGACCTGAGTGGCTGCTA3' (Seq. ID#1)
  • SKC RPl 5' CGG GAT CCT TAT TTG TCG TTA GGG TTT ATC AGG 3' (Seq. ID#2).
  • the transformants were screened by isolating plasmid from 1 ml of culture by mini lysis method and was digested with restriction enzymes BamHI and Xbal (NEB) to release the insert. The digestion was carried out at 37 0 C for 2 hours.
  • One positive clone was selected and inoculated to LB medium containing Ampicillin 100 ⁇ g/ml and plasmid was isolated by Qiagen mini prep kit and the plasmid was sequenced to confirm the presence of the gene and any possible mutations. The sequence confirmed plasmid was then used for further sub-cloning.
  • Sub cloning SKC coding DNA fragment to pET vector The plasmid which has the SKC gene in pTZ57R/T vector was digested with the restriction enzymes Ndel and BamHI and electrophoresed on 1% agarose gel. The insert released was excised and gel eluted and ligated to pET vector which was also digested with the same enzymes. The ligation was done using the enzyme T4 DNA ligase (NEB) and ligation was carried out at 16 0 C overnight. The ligation mix is used to transform competent E.coli DH5 alpha cells and the transformants were selected on LB plates with 100 ⁇ g/ml Ampicillin. The transformants are screened for the presence of the SKC gene. The correct clone (Fig. 1) was mapped and confirmed and this plasmid is used for transforming competent E.coli BL26 (DE3) host.
  • T4 DNA ligase N4 DNA ligase
  • E.coli BL26 (DE3) host The verified plasmid clone was transformed to E.coli BL26 (DE3) host and the transformants were selected on Ampicillin (100 ⁇ g/ml) plates. A few transformants were grown in LB Ampicillin (lOO ⁇ g/ml) liquid media and when the OD at 600nm is -0.6 to 0.8 the cells are induced with IPTG (1 mM). The induction is carried out overnight at 30 0 C and the cells were pelleted and resuspended in buffer and sonicated to lyse the cells. The samples were loaded on SDS-PAGE. The results are shown in Fig. 2. A good level of induction was observed. Recombinant SKC was purified and sequencing of the product showed that only 40% of the rSKC molecules were Met 0 SKC.
  • the main goal of this experiment was to determine if over expression of MAP in the same cell as that expressing rSKC would help in efficient removal of N-terminal methionine.
  • E.coli MAP gene was amplified from BL21 (DE3) host genomic DNA using the following primers (Seq. ID# 3 to Seq. ID# 10) to generate a mutated version which has been reported to remove N-terminal methionine more efficiently from proteins with He as the penultimate amino acid (Liao YD, Jeng JC, Wang CF, Wang SC, Chang ST., Protein Science. 13:1802-1810, 2004, US Patent 7109015).
  • the mutations introduced were 168Y, 206M, 233Q.
  • the primer positions have been represented in the following figure.
  • MAP Methionine amino peptidase
  • the four PCR reactions were run on 1.2% agarose gel for 1 hr at 100 mV. Individually the amplified fragments were excised from the gel and purified using Qiagen gel extraction kit. To get full length MAP gene (1048kb), all the four fragments were used as template using MetAPFP & MetAPRP primers. Proof reading Pwo polymerase (Roche) was used for PCR and the full length MAP gene was amplified. The amplified product was electrophoresed on 1% agarose gel and was purified using the gel extraction kit (Qiagen).
  • the gel purified product was modified to have dATP overhangs and this product was ligated to pTZ57R/T vector (MBI Fermentas). The ligation reaction was carried out at 16 0 C overnight. The ligation mix was transformed to chemically competent E. coli DH5 ⁇ cells, plated on LB Ampicillin (lOO ⁇ g/ml) plates incubated at 37 0 C, overnight. The transformants were screened by isolating plasmid from 1 ml of culture by mini lysis method and was digested with restriction enzymes BamHI and Xbal (NEB) to release the insert. The digestion was carried out at 37 0 C for 2 hours.
  • BamHI and Xbal restriction enzymes BamHI and Xbal
  • Sub-cloning MAP (Seq. ID #18) gene to pACYC vector;
  • the plasmid with the MAP gene in pTZ57R/T vector was digested with the restriction enzymes Sail followed by BamHI and was electrophoresed on 1% agarose gel.
  • the insert released was excised from the gel, eluted and ligated to pACYC vector which was also digested with the same enzymes sequentially.
  • the ligation was done using the enzyme T4 DNA ligase (NEB) and ligation wais carried out at 16 0 C overnight.
  • the ligation mix was used to transform competent E.coli DH5D cells and the transformants were selected on LB plates with Chloramphenicol (15 ⁇ g/ml). The transformants were screened for the presence of the MAP gene.
  • the correct clone was mapped and confirmed (Fig. 3).
  • E.coli BL26 (DE3) host The verified plasmid clone was co- transformed along with pET SKC vector to E.coli BL26 (DE3) host and the transformants were selected on Ampicillin (100 ⁇ g/ml) and Chloramphenicol (15 ⁇ g/m)l plates. A few transformants were grown in LB broth with Ampicillin (lOO ⁇ g/ml) and Chloramphenicol (15 ⁇ g/ml). When the OD at 600 nm was -0.6 to 0.8 the cells were induced with IPTG (1 mM). The induction was carried out overnight at 30 0 C and the cells were pelleted and resuspended in buffer and sonicated to lyse the cells. The samples were loaded on SDS-PAGE.
  • SMT-3 gene was amplified.
  • the reaction mix was electrophoresed on 1.2% agarose gel.
  • the amplified product was checked for the size and was gel eluted and was used as the template for overlapping PCR.
  • SMT-SKC FPl 5' GAACAGATTGAAGGTATTGCTGGACCTGAGTGGCTG 3', Seq.
  • SMT-SKC RPl (5'CGG GAT CCT TAT TTG TCG TTA GGG TTT ATC AGG 3', Seq. ID# 14) the SKC gene was amplified by PCR using proof reading polymerase. This fragment was also gel eluted and used as template for overlapping PCR. By mixing both the purified PCR products and using them as the template, PCR was performed to get the full length overlapped product. This is electrophoresed on 1% agarose gel and the product is gel eluted. This is then ligated to pTZ57R/T vector by creating dATP overhangs and the ligation was carried out at 16°C overnight.
  • the ligation mix is then transformed to competent E.coli DH5 ⁇ cells and the mix was plated on LB containing Ampicillin (100 ⁇ g/ml) plates and the plates were incubated at 37°C incubator overnight.
  • the transformants which appear were screened for the presence of the gene and this plasmid was purified by using Qiagen mini prep kit.
  • This plasmid was sequenced to confirm the overlap and for mutations. The confirmed plasmid was used for further experiments.
  • This plasmid was digested with the restriction enzymes Ndel and BamHI (NEB) and the reaction mix was incubated at 37°C for 2 hours. The reaction was terminated by heat inactivation of the enzymes and it was electrophoresed on 1% agarose gel.
  • the insert released was gel eluted and was used for ligation with the vector.
  • the vector is prepared by digesting pET vector with the enzymes Ndel and BamHI and processed in a similar way as done to the insert. Then a ligation reaction was set using T4 DNA ligase (NEB) and the reaction was carried out at 16°C overnight. The ligation mix was then transformed to competent E.coli DH5 ⁇ cells and then selected on LB Kanamycin (25 ⁇ g/ml) plates. The transformants were screened for the presence of the gene and the plasmid was isolated from the correct clone using Qiagen Mini prep kit. The plasmid was confirmed by restriction analysis and was then used for expression studies.
  • FIG. 6 Schematic representation of SMT3 AND SKC genefusion is illustrated in Fig: 6.
  • the plasmid containing SMT3-SKC fused gene (Fig: 7) product in pET vector was used to transform competent E.coli BL21 (DE3) cells. The transformants were selected on LB containing Kanamycin (25 ⁇ g/ml) plates. A few colonies were inoculated to 100 ml LB containing Kanamycin (25 ⁇ g/ml) and were grown to OD 600 of ⁇ 0.7-0.8. A small sample was removed as control and the rest of the culture was induced with IPTG to a final concentration of 1 mM. The induction was performed overnight at 30 0 C with shaking at 120 rpm. The cells were then pelleted and resuspended in buffer and sonicated to lyse the cells and the samples were analyzed on 10% SDS-PAGE.
  • Example 4 Cloning and expression of UIpI protease in E.coli
  • the ULPl (Seq. Id # 19) gene was amplified by PCR using Saccharomyces cerevisiae genomic DNA as the template (BICC# 7806) and proof reading Pwo polymerase (Roche) enzyme.
  • the PCR product was gel purified and cloned to pTZ57R/T vector (MBI Fermentas) after creating dATP overhangs. The ligation was carried over night at 16 °C. The ligation mix was transformed to competent E.coli DH5 ⁇ cells and selected on LB Ampicillin (lOO ⁇ g/ml) plates. The colonies were screened by PCR using M 13 forward and M 13 reverse primers and gene specific forward and reverse primers. One correct clone was selected and plasmid from this clone was isolated by using Qiagen mini prep method. This clone was sequenced to confirm the presence of the gene and any possible mutations Results of sequencing of the PCR product showed three mutations.
  • the transformation mix was then plated on LB plates carrying Kanamycin (25 ⁇ g/ml) and the plates were incubated at 37 0 C overnight.
  • the Kanamycin resistant transformants were screened for the presence of the gene and the correct clone was inoculated to LB medium with Kanamycin (25 ⁇ g/ml) and plasmid was isolated by using Qiagen mini prep kit.
  • Example 5 After overnight IPTG induction, the OD at 600 nm was checked and the cells were pelleted by centrifugation at 6000 rpm for 6 minutes. The cells were then resuspended in a buffer (100 mM Tris buffer, pH 8.0 with 0.1M NaCl) and sonicated using Branson sonifier till the OD dropped to 1/5 -1/8 of the initial OD. The soluble fraction was loaded on to Ni-NTA agarose matrix.(Qiagen) which was equilibrated with the same buffer. The matrix was washed with the same buffer and the protein was eluted from the matrix using the same buffer supplemented with 250 mM Imidazole. The results are shown in Fig. 5. A good level of induction (and UIp 1 production) was observed and the His-tagged UIp 1 was purified on Ni-NTA column chromatography.
  • Example 5 A good level of induction (and UIp 1 production) was observed and the His-tagged UIp 1 was purified
  • the Ulpl protease encoding DNA fragment which was cloned to pET vector was digested with the restriction enzymes Ndel and BsrBI (NEB) and the digestion is carried out by incubating the reaction mix at 37 0 C. The reaction mix was then heated to high temperature to inactivate the enzymes and electrophoresed in l%agarose gel. The fragment released is then gel eluted and is ligated to pTrc99A vector which was also digested with the enzymes Ndel and Smal and was treated in similar manner. The ligation reaction was carried out using T4 DNA ligase (NEB) and the reaction was carried out at 16 0 C overnight.
  • Ndel and BsrBI Ndel and BsrBI
  • the ligated sample was then used to transform chemically competent E.coli DH5 ⁇ cells and plated on LB Ampicillin (100g/ml) plates.
  • the transformants which were resistant to Ampicillin (100g/ml) were screened for the presence of the insert by PCR using the gene specific primers.
  • One correct clone was identified and used for further experiments.
  • Sub cloning Ulpl coding sequence to pACYC184 vector The Ulpl gene which was cloned to pTrc99A vector was digested with enzymes PvuII and BamHI (NEB) and the digestion was carried out at 37 0 C for 2 hours.
  • the reaction was stopped by heat inactivating the enzymes and the mix was electrophoresed on 1% agarose gel.
  • the insert released was gel purified and used for ligation with the vector.
  • the pACYC184 vector was prepared by digesting with enzymes EcoRV and BamHI.The restriction enzyme digested pACYC184 vector was purified in a similar manner (Fig: 8).
  • the insert and the vector were ligated using T4 DNA ligase.
  • the ligated sample was transformed to competent DH5 ⁇ cells and plated on LB agar plates containing Chloramphenicol (lO ⁇ g/ml). The plates were incubated at 37 0 C overnight.
  • Chloramphenicol resistant transformants were screened and the correct clone was confirmed by restriction analysis.
  • This plasmid was used for further experiments.
  • This pACYC184 vector with insert of UIp 1 gene in was co-transformed along with the plasmid harboring SMT3-SKC gene to chemically competent E.coli BL21 (DE3) host and plated on LB plates with Chloramphenicol (10 g/ml) & Kanamycin (25 g/ml). The plates were incubated at 37°C overnight. The transformants which appeared were resistant to both the antibiotics indicating the presence of both the plasmids.
  • a few transformants were inoculated to 100 ml of LB medium containing both the antibiotics and the flask was incubated on a shaker at 37 0 C. When the OD at 600 nm reached ⁇ 0.7-0.8, a small sample was removed as control and the rest of the culture was induced with IPTG to a final concentration of 1 mM. The culture was next incubated at 30 0 C with shaking at 120 rpm overnight. The OD at 600 nm of the culture at the end of induction was checked and the cells were pelleted by centrifugation. The cell pellet was resuspended in a buffer containing 20 mM Tris, pH 8.0 and 100 mM NaCl.
  • OD at 600 nm was checked and the volume was adjusted to -20-25 OD and the cells were sonicated using a cell disruptor, keeping on ice so that the temperature does not increase.
  • the samples were loaded on 10% SDS-PAGE gel (Fig. 4). The cleavage was very efficient when both the protease and SMT3-SKC (Seq Id #21) were co expressed in the same host.
  • the SKC was purified from lysed E.coli cells by standard purification methods. N-terminus of all the purified rSKC molecules was confirmed to be free of methionine.
  • Met SKC and Met free SKC were purified and analyzed for biological activity in solution chromogenic assay and Fibrin clear clot assay (Illustrated in Fig:9).
  • the third international reference standard for Streptokinase (NIBSC Batch # 00/464 derived from Native Streptokinase) was used to calculate the relative potency and activity. The ratio of the activity for the two streptokinase preparations by these two methods was calculated and is presented in the table below
  • Seq. ID#1 CAT ATG ATT GCT GGA CCT GAG TGG CTG CTA Seq. ID#2
  • Nucleotide sequence of the ULPl PCR product amplified using Saccharomyces cerevisiae genome as template.
  • the PCR product amplified nucleotides encoding amino acids 403-621 of ULPl protein.
  • the silent nucleotide substitutions are shown in bold and underlined.
  • SMT3-SKC fusion protein Amino acid sequence of SMT3-SKC fusion protein.
  • the sequence of SMT3 is shown in bold letters. 1 MGHHHHHHGS DSEVNQEAKP EVKPEVKPET HINLKVSDGS SEIFFKIKKT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de fabrication de polypeptides exempts de méthionine N-terminale dans une cellule hôte microbienne recombinante et des compositions pharmaceutiques contenant également un ou plusieurs excipients pharmaceutiques pour la gestion de divers troubles thérapeutiques. L'invention concerne notamment la fabrication d'hormones de croissance ou de streptokinases exemptes de méthionine N-terminale par co-expression avec une enzyme protéase dans E. coli.
PCT/IN2007/000012 2006-11-30 2007-01-12 Procédé de fabrication de polypeptides exempts de méthionine n-terminale dans des cellules hôtes microbiennes WO2008065673A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2009005764A MX2009005764A (es) 2006-11-30 2007-01-12 Metodo para producir polipeptidos libres de metionina n-terminal en celulas huesped microbianas.
EP07706183A EP2097520A4 (fr) 2006-11-30 2007-01-12 Procede de fabrication de polypeptides exempts de methionine n-terminale dans des cellules hotes microbiennes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2217/CHE/2006 2006-11-30
IN2217CH2006 2006-11-30

Publications (1)

Publication Number Publication Date
WO2008065673A1 true WO2008065673A1 (fr) 2008-06-05

Family

ID=39467497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000012 WO2008065673A1 (fr) 2006-11-30 2007-01-12 Procédé de fabrication de polypeptides exempts de méthionine n-terminale dans des cellules hôtes microbiennes

Country Status (3)

Country Link
EP (1) EP2097520A4 (fr)
MX (1) MX2009005764A (fr)
WO (1) WO2008065673A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533712A (zh) * 2009-05-12 2012-07-04 中国科学院上海生命科学研究院 一种固相化sumo化系统及固相化去sumo化系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763215A (en) * 1984-08-16 1998-06-09 Bio-Technology General Corporation Method of removing N-terminal amino acid residues from eucaryotic polypeptide analogs and polypeptides produced thereby
WO1998038290A1 (fr) * 1997-02-28 1998-09-03 Lg Chemical Ltd. Aminopeptidase derivee de bacillus licheniformis et procede de preparation de proteines de type naturel
EP0629695B1 (fr) * 1993-06-17 2001-09-26 Lucky Ltd. Nouvelle aminopeptidase de streptomyces
US7109015B2 (en) * 2004-03-29 2006-09-19 Academia Sinica Removal of N-terminal methionine from proteins by engineered methionine aminopeptidase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060461B2 (en) * 2002-01-07 2006-06-13 Lifesensors, Inc. Methods and compositions for protein expression and purification
WO2006073976A2 (fr) * 2004-12-30 2006-07-13 Lifesensors, Inc. Compositions, procedes et kits permettant d'ameliorer l'expression, la solubilite et l'isolation des proteines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763215A (en) * 1984-08-16 1998-06-09 Bio-Technology General Corporation Method of removing N-terminal amino acid residues from eucaryotic polypeptide analogs and polypeptides produced thereby
EP0629695B1 (fr) * 1993-06-17 2001-09-26 Lucky Ltd. Nouvelle aminopeptidase de streptomyces
WO1998038290A1 (fr) * 1997-02-28 1998-09-03 Lg Chemical Ltd. Aminopeptidase derivee de bacillus licheniformis et procede de preparation de proteines de type naturel
US7109015B2 (en) * 2004-03-29 2006-09-19 Academia Sinica Removal of N-terminal methionine from proteins by engineered methionine aminopeptidase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCHI E. ET AL.: "A new human growth hormone production process using a recombinant Bacillus subtilis strain", JOURNAL OF BIOTECHNOLOGY, vol. 18, 1991, pages 41 - 54, XP023944280 *
HERMENTIN P. ET AL.: "Comparative analysis of the activity and content of different stretokinase preparations", EUROPEAN HEART JOURNAL, vol. 26, 2005, pages 933 - 940, XP008109608 *
LIAO Y.D. ET AL.: "Removal of N-terminal methionine from recombinant proteins by engineered E.coli methionine aminopeptidase", PROTEIN SCIENCE, vol. 13, 2004, pages 1802 - 1810, XP008043171 *
See also references of EP2097520A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533712A (zh) * 2009-05-12 2012-07-04 中国科学院上海生命科学研究院 一种固相化sumo化系统及固相化去sumo化系统

Also Published As

Publication number Publication date
EP2097520A4 (fr) 2012-07-04
EP2097520A1 (fr) 2009-09-09
MX2009005764A (es) 2009-08-24

Similar Documents

Publication Publication Date Title
US8034910B2 (en) SUMO fusion protein expression system for producing native proteins
EP0682709A1 (fr) Proteines de fusion comportant un site de coupure reconnu par une protease virale de plante
US20090186380A1 (en) Method of secretory expression of lysostaphin in escherichia coli at high level
NO863596L (no) Enbakteriell metionin n-terminal peptidase.
JP2012531198A (ja) Ｃｒｍ１９７及びその誘導体の産生のための人工遺伝子の細菌発現
CN102643847A (zh) 多基因共表达体系及含二硫键功能性蛋白的生产方法
CN114381471B (zh) 一种辅助蛋白在重组蛋白生产中的应用及融合表达系统
CN1970574B (zh) 溶栓和抗凝双重功效融合蛋白、制备方法及其应用
WO2014187960A1 (fr) Élimination des extensions n-terminales de protéines de fusion
US8530217B2 (en) Processing of peptides and proteins
AU2021264001A1 (en) Methods of producing full-length antibodies using e.coli
EP4107281A1 (fr) Procédés d'ingénierie d'enzymes amino acide ammonia lyase et enzymes ainsi obtenues
EP2097520A1 (fr) Procede de fabrication de polypeptides exempts de methionine n-terminale dans des cellules hotes microbiennes
RU2453604C1 (ru) Гибридный белок (варианты), штамм бактерий escherichia coli - продуцент гибридного белка (варианты) и способ получения безметионинового интерферона альфа-2 человека
RU2441072C1 (ru) ГИБРИДНЫЙ БЕЛОК, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА И СПОСОБ ПОЛУЧЕНИЯ БЕЗМЕТИОНИНОВОГО ИНТЕРФЕРОНА АЛЬФА-2b ЧЕЛОВЕКА ИЗ ЭТОГО ГИБРИДНОГО БЕЛКА
EP1697509B1 (fr) Traitement de peptides et de proteines
CN112574286A (zh) 多肽及其应用
CN106749605B (zh) 一种人神经生长因子类似物及其制备方法
JP4663524B2 (ja) ＯｍｐＴプロテアーゼ変異体を用いたポリペプチドの切断方法
CN101736022B (zh) 人可溶性鸟苷酸环化酶的高效制备方法
CN112055751B (zh) 修饰型酯酶和其用途
CN102250933A (zh) 利用双质粒系统在大肠杆菌中表达瑞替普酶的方法
KR100202958B1 (ko) 인슐린 융합단백질로부터 인슐린을 생산하는데 있어서 효소적 절단을 가능케하는 인슐린 융합단백질 유전자를 가진 발현벡터 및 이를 이용한 사람 인슐린의 제조방법
JP5020487B2 (ja) 融合タンパク質発現用新規ｄｎａ及び該ｄｎａを用いたタンパク質の製造方法
KR100899173B1 (ko) 인간 유래 조직형 플라스미노겐 활성화 인자의 대량발현용 재조합 유전자 및 그 단백질의 재구성 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07706183

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007706183

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/005764

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载